Workflow
工业大麻
icon
Search documents
奥瑞金跌2.08%,成交额1.18亿元,主力资金净流出1069.81万元
Xin Lang Cai Jing· 2025-09-18 06:00
Company Overview - Aorijin Technology Co., Ltd. is located in Yanqi Industrial Development Zone, Huairou District, Beijing, established on May 14, 1997, and listed on October 11, 2012. The company specializes in the research, design, production, and sales of metal packaging products for food and beverages [1] - The main business revenue composition includes metal packaging products and services at 93.31%, other supplementary services at 6.14%, and filling services at 0.55% [1] Financial Performance - As of June 30, 2025, Aorijin achieved operating revenue of 11.727 billion yuan, representing a year-on-year growth of 62.74%, and a net profit attributable to shareholders of 903 million yuan, with a year-on-year increase of 64.66% [2] - Cumulative cash dividends since Aorijin's A-share listing amount to 3.912 billion yuan, with 923 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of Aorijin shareholders is 45,100, a decrease of 7.40% from the previous period, while the average circulating shares per person increased by 7.99% to 56,685 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third-largest shareholder with 74.7592 million shares, an increase of 4.8132 million shares from the previous period [3]
顺灏股份跌2.03%,成交额1.82亿元,主力资金净流出2980.53万元
Xin Lang Cai Jing· 2025-09-17 05:58
Company Overview - Shanghai Shunhao New Materials Technology Co., Ltd. was established on December 21, 2004, and listed on March 18, 2011. The company is located at 200 Zhenchen Road, Putuo District, Shanghai [2] - The main business includes research, production, processing, and sales of vacuum aluminum-coated paper, composite film paper, white cardboard, printed products, and cigarette polypropylene fiber bundles [2] - The revenue composition is as follows: printed products 48.07%, aluminum-coated paper 30.03%, others (supplement) 8.51%, composite film paper 5.56%, others 3.93%, optical anti-counterfeiting film 2.02%, new tobacco 1.65%, and white cardboard 0.23% [2] Financial Performance - For the first half of 2025, the company achieved operating revenue of 620 million yuan, a year-on-year decrease of 12.19%. The net profit attributable to the parent company was 33.30 million yuan, a year-on-year increase of 23.11% [2] - Since its A-share listing, the company has distributed a total of 427 million yuan in dividends, with 68.81 million yuan distributed in the last three years [3] Stock Performance - On September 17, the stock price of Shunhao fell by 2.03%, trading at 7.24 yuan per share, with a total market capitalization of 7.674 billion yuan [1] - Year-to-date, the stock price has increased by 141.25%, but it has decreased by 5.73% in the last five trading days and 14.72% in the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on July 22, where it recorded a net buy of -21.52 million yuan [1] Shareholder Information - As of June 30, the number of shareholders was 46,100, a decrease of 11.52% from the previous period. The average circulating shares per person increased by 13.01% to 23,011 shares [2]
云南城投涨2.26%,成交额1.51亿元,主力资金净流出1461.89万元
Xin Lang Zheng Quan· 2025-09-16 03:25
Group 1 - Yunnan Chengtou's stock price increased by 2.26% on September 16, reaching 2.72 CNY per share, with a trading volume of 1.51 billion CNY and a turnover rate of 3.51%, resulting in a total market capitalization of 4.367 billion CNY [1] - Year-to-date, Yunnan Chengtou's stock price has risen by 1.87%, with a 12.86% increase over the last five trading days, a 9.68% increase over the last 20 days, and a 15.74% increase over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on April 11, where it recorded a net purchase of 26.75 million CNY [1] Group 2 - Yunnan Chengtou was established on April 21, 1997, and listed on December 2, 1999, with its main business activities including real estate development, land development, property management, and rental of commercial properties [2] - The company's revenue composition includes commercial management (43.12%), property services (21.10%), real estate (19.73%), hotel operations (12.07%), other income (2.53%), and interest income (1.47%) [2] - As of August 8, 2025, the number of shareholders was 54,500, a decrease of 0.55%, with an average of 29,489 circulating shares per person, an increase of 0.55% [2] Group 3 - Yunnan Chengtou has distributed a total of 707 million CNY in dividends since its A-share listing, with no dividends distributed in the last three years [3] - As of June 30, 2025, the top ten circulating shareholders included the Southern CSI Real Estate ETF, which held 12.2685 million shares, an increase of 189,800 shares compared to the previous period [3]
东峰集团跌2.07%,成交额1.56亿元,主力资金净流入181.48万元
Xin Lang Cai Jing· 2025-09-15 06:28
Core Viewpoint - Dongfeng Group's stock price has shown fluctuations, with a year-to-date increase of 18.59% but a recent decline of 1.87% over the last five trading days [2] Financial Performance - As of June 30, 2025, Dongfeng Group reported a revenue of 604 million yuan, a year-on-year decrease of 12.37%, while the net profit attributable to shareholders was -61.31 million yuan, reflecting a year-on-year increase of 52.87% [2] - The company has cumulatively distributed 4.134 billion yuan in dividends since its A-share listing, with 46.0741 million yuan distributed over the past three years [3] Stock Market Activity - On September 15, Dongfeng Group's stock price fell by 2.07%, trading at 4.72 yuan per share with a total market capitalization of 8.847 billion yuan [1] - The stock has been active in the market, appearing on the "Dragon and Tiger List" three times this year, with the most recent occurrence on January 24 [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased to 35,600, with an average of 52,617 circulating shares per person, a decrease of 0.89% from the previous period [2] - Hong Kong Central Clearing Limited is the ninth largest circulating shareholder, holding 12.9195 million shares, an increase of 2.2956 million shares from the previous period [3] Business Overview - Dongfeng Group, established on December 30, 1983, specializes in the design, production, and sales of cigarette labels and related packaging materials, with its main revenue sources being pharmaceutical packaging (41.31%), membrane new materials (34.19%), and paper products (14.47%) [2]
云南城投跌2.26%,成交额1.22亿元,主力资金净流出1803.26万元
Xin Lang Cai Jing· 2025-09-15 02:21
Company Overview - Yunnan Chenggong Investment Co., Ltd. is located in Kunming, Yunnan Province, and was established on April 21, 1997, with its listing date on December 2, 1999 [2] - The company's main business includes real estate development, land primary development, property management, and commercial housing leasing [2] - The revenue composition is as follows: commercial management 43.12%, property services 21.10%, real estate 19.73%, hotel operations 12.07%, other income 2.53%, and interest income 1.47% [2] Financial Performance - For the first half of 2025, Yunnan Chenggong reported operating revenue of 918 million yuan, a year-on-year decrease of 1.70% [2] - The net profit attributable to the parent company was -37.72 million yuan, a year-on-year decrease of 191.80% [2] - The company has cumulatively distributed 707 million yuan since its A-share listing, with no distributions in the last three years [3] Stock Performance - As of September 15, the stock price of Yunnan Chenggong fell by 2.26% to 2.59 yuan per share, with a total market capitalization of 4.159 billion yuan [1] - Year-to-date, the stock price has decreased by 3.00%, but it has increased by 7.92% over the last five trading days, 5.71% over the last 20 days, and 10.68% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on April 11, where it recorded a net purchase of 26.75 million yuan [1] Shareholder Information - As of August 8, the number of shareholders was 54,500, a decrease of 0.55% from the previous period, with an average of 29,489 circulating shares per person, an increase of 0.55% [2] - As of June 30, 2025, the fourth largest circulating shareholder is the Southern CSI Real Estate ETF, holding 12.2685 million shares, an increase of 189,800 shares from the previous period [3]
仁和药业涨2.05%,成交额1.87亿元,主力资金净流出179.66万元
Xin Lang Cai Jing· 2025-09-05 04:16
Core Viewpoint - Renhe Pharmaceutical's stock has shown a positive trend with a year-to-date increase of 15.51%, reflecting strong market interest and performance in the pharmaceutical sector [1][2]. Company Overview - Renhe Pharmaceutical, established on December 4, 1996, and listed on December 10, 1996, is located in Nanchang, Jiangxi Province. The company specializes in the production and sale of traditional Chinese and Western medicines, raw materials, and health-related products [1]. - The company's revenue composition includes 70.25% from pharmaceuticals, 27.79% from health-related products, and 1.95% from other business products [1]. Financial Performance - For the first half of 2025, Renhe Pharmaceutical reported a revenue of 1.975 billion yuan, a year-on-year decrease of 16.46%, and a net profit attributable to shareholders of 290 million yuan, down 13.87% compared to the previous year [2]. - The company has distributed a total of 1.962 billion yuan in dividends since its A-share listing, with 770 million yuan distributed over the last three years [3]. Shareholder Information - As of June 30, 2025, Renhe Pharmaceutical had 104,400 shareholders, a decrease of 2.76% from the previous period. The average number of tradable shares per shareholder increased by 2.84% to 12,748 shares [2]. - Major shareholders include Hong Kong Central Clearing Limited, which holds 11.4865 million shares, and Southern CSI 1000 ETF, holding 10.3367 million shares, both of which have increased their holdings [3].
恒丰纸业涨2.04%,成交额7026.53万元,主力资金净流入179.01万元
Xin Lang Cai Jing· 2025-09-04 05:32
Core Viewpoint - Hengfeng Paper's stock price has shown significant growth this year, with a year-to-date increase of 33.42%, despite a slight decline in the last five trading days [2]. Group 1: Stock Performance - As of September 4, Hengfeng Paper's stock price rose by 2.04% to 10.02 CNY per share, with a trading volume of 70.27 million CNY and a turnover rate of 2.38%, resulting in a total market capitalization of 2.993 billion CNY [1]. - The stock has experienced a 0.79% decline over the last five trading days, a 9.87% increase over the last 20 days, and a 25.56% increase over the last 60 days [2]. Group 2: Financial Performance - For the first half of 2025, Hengfeng Paper reported a revenue of 1.353 billion CNY, representing a year-on-year growth of 12.78%, and a net profit attributable to shareholders of 94.94 million CNY, which is a 69.06% increase compared to the previous year [2]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Hengfeng Paper was 16,600, a decrease of 4.78% from the previous period, with an average of 17,980 circulating shares per shareholder, an increase of 5.02% [2]. - The company has distributed a total of 680 million CNY in dividends since its A-share listing, with 115 million CNY distributed over the last three years [3]. Group 4: Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, CITIC Prudential Multi-Strategy Mixed Fund (LOF) A is the fifth largest shareholder with 3.2173 million shares, marking its entry as a new shareholder [4].
通化金马涨2.03%,成交额2.30亿元,主力资金净流出669.63万元
Xin Lang Cai Jing· 2025-09-01 03:18
Core Viewpoint - Tonghua Jinma's stock price has shown a significant increase of 54.01% year-to-date, despite a recent decline in the last five trading days [1][2]. Company Overview - Tonghua Jinma Pharmaceutical Group Co., Ltd. is located in Tonghua City, Jilin Province, and was established on February 26, 1993. It was listed on April 30, 1997. The company focuses on the research, production, and sales of pharmaceuticals, with 100% of its revenue derived from the pharmaceutical industry [1]. Financial Performance - For the first half of 2025, Tonghua Jinma achieved an operating income of 650 million yuan, representing a year-on-year growth of 0.12%. The net profit attributable to shareholders was 16.80 million yuan, showing a significant increase of 34.77% compared to the previous year [2]. Stock Performance - As of September 1, the stock price was 24.18 yuan per share, with a market capitalization of 23.37 billion yuan. The trading volume was 230 million yuan, with a turnover rate of 0.99% [1]. - The stock has experienced a net outflow of 6.69 million yuan from main funds, with large orders accounting for 30.51% of total buying and 29.38% of total selling [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 39,500, a rise of 6.54%. The average number of circulating shares per person decreased by 6.13% to 24,457 shares [2]. - The top ten circulating shareholders include notable entities such as Innovation Drug and Southern CSI 1000 ETF, with changes in their holdings noted [3]. Dividend Information - Since its A-share listing, Tonghua Jinma has distributed a total of 210 million yuan in dividends, with no dividends paid in the last three years [3].
仁和药业涨2.09%,成交额1.50亿元,主力资金净流入716.67万元
Xin Lang Cai Jing· 2025-09-01 03:18
Company Overview - Renhe Pharmaceutical Co., Ltd. is located in Nanchang, Jiangxi Province, and was established on December 4, 1996, with its listing date on December 10, 1996 [1] - The company primarily engages in the production and sales of traditional Chinese medicine, Western medicine, raw materials, and health-related products, with a revenue composition of 70.25% from pharmaceuticals, 27.79% from health-related products, and 1.95% from other business products [1] Financial Performance - For the first half of 2025, Renhe Pharmaceutical reported a revenue of 1.975 billion yuan, a year-on-year decrease of 16.46%, and a net profit attributable to shareholders of 290 million yuan, down 13.87% year-on-year [2] - The company has cumulatively distributed 1.962 billion yuan in dividends since its A-share listing, with 770 million yuan distributed over the past three years [3] Stock Market Activity - As of September 1, Renhe Pharmaceutical's stock price increased by 2.09% to 6.35 yuan per share, with a trading volume of 150 million yuan and a turnover rate of 1.80%, resulting in a total market capitalization of 8.89 billion yuan [1] - The stock has seen a year-to-date increase of 13.19%, a decline of 3.93% over the last five trading days, a rise of 6.37% over the last 20 days, and an increase of 14.21% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on August 21 [1] Shareholder Information - As of June 30, 2025, Renhe Pharmaceutical had 104,400 shareholders, a decrease of 2.76% from the previous period, with an average of 12,748 circulating shares per shareholder, an increase of 2.84% [2] - Major shareholders include Hong Kong Central Clearing Limited, holding 11.4865 million shares, and Southern CSI 1000 ETF, holding 10.3367 million shares, both of which have increased their holdings compared to the previous period [3]
美股异动|工业大麻股继续活跃 据称特朗普考虑将大麻归入危险性较低药物
Ge Long Hui· 2025-08-13 13:55
Core Insights - The industrial hemp stocks are experiencing significant activity, with Tilray rising over 9%, Harrow and Veru increasing by more than 6%, and Aurora Cannabis up nearly 2% [1] - A report from the Washington Post indicates that Trump expressed intentions to classify cannabis as a lower-risk substance during a fundraising dinner in New Jersey, which could simplify the cannabis trade and enhance profitability in this multi-billion dollar industry [1] - Trump is expected to make decisions regarding cannabis in the coming weeks, which could have substantial implications for the market [1] Company Performance - Tilray's stock increased by over 9% [1] - Harrow and Veru both saw stock increases of more than 6% [1] - Aurora Cannabis experienced a rise of nearly 2% [1] - Other companies like Canopy Growth and Teva Pharmaceuticals also saw stock increases of over 1.5% [1]